Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study

Abstract

Background: Osimertinib (Osi) is an EGFR-TKI that potently inhibits both EGFR-sensitizing and EGFR T790Mresistancemutations in non-small cell lung cancer (NSCLC). Identification of oligo-progression (PD) onOsimay allow local treatment and continuation of Osi. Metastatic patterns at the time of acquired resistance to Osi are poorly understood. Method(s): We retrospectively analyzed 50 pre-treated T790M+ NSCLC patients who received Osi at 7 Swiss centers. Oligo-PD was defined as PD in